U.S. Pharmacist Weekly News
|
Major Bleeding Might Be Riskier Than Assumed in Unprovoked VTE Patients
|
|
Clinical guidelines recommend that unprovoked venous thromboembolism (VTE) be treated with anticoagulation for at least 3 months. A new meta-analysis underscores why it is so important that decisions about longer courses of treatment take into account the potential risk for a major bleeding event. Here is more information.
|
|
|
FDA Considering Boosters Mid-Month for Other Authorized COVID-19 Vaccine
|
|
|
Pharmacists should prepare for an onslaught of COVID-19 booster-vaccine seekers by the end of the month. The FDA says it will take up the issue of Moderna and Janssen boosters at mid-month, as well as consider whether vaccine recipients can mix doses from different manufacturers. Here is more information.
|
|
Longer Use of Enzyme-Inducing Antiseizure Drugs Linked to CVD Risk
|
|
|
In contrast to a study a few months ago, new research that had a longer study period and involved more epilepsy patients has identified a link between enzyme-inducing antiseizure medications and increased risk of cardiovascular disease (CVD). Find out what the authors believe are the most important factors involved in the heightened risk.
|
|
|
Here’s How to Get Older Adults’ Attention Before They Use OTC Drugs
|
|
Older adults frequently experience adverse effects from OTC drugs. A new study sought to determine what critical information needs to be emphasized on Drug Facts Labels to help avoid those results. Find out what surveyed pharmacists suggested were the most important messages.
|
|
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
